Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review

Yanish Soorojebally(Université de Versailles Saint-Quentin-en-Yvelines), François Audenet(Université Paris Cité), Pierre‐Jean Lamy(Montpellier GenomiX), Y. Neuzillet(Université de Versailles Saint-Quentin-en-Yvelines), Thierry Lebrét(Université de Versailles Saint-Quentin-en-Yvelines), M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Xavier Rébillard(Clinique du Millénaire), Morgan Rouprêt(Sorbonne Université), Sophie Ferlicot(Université Paris-Sud), Yves Allory(Institut Curie), Diana Kassab‐Chahmi(Lymphoma Study Association), Françoise Descôtes(Lyon 1 Université), Catherine Roy(Hôpital Civil, Strasbourg)
World Journal of Urology
January 2, 2023
10.1007/s00345-022-04253-3
Cited by 42

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532